【摘要】 目的对比分析常规治疗与布地奈德雾化吸入法治疗小儿肺炎的临床疗效。方法随机将该院儿科收治的小儿肺炎患儿97例分成两组(2018年2—10月),给予参照组48例小儿肺炎患儿实施常规疗法开展治疗,给予治疗组49例小儿肺炎患儿在常规疗法前提下开展布地奈德雾化吸入治疗,对比两组小儿肺炎患儿的治疗效果差异。结果治疗组小儿肺炎患儿治疗后的症状缓解时间、VC水平、FEV1水平、MVV水平优于参照组小儿肺炎患儿,差异有统计学意义(P<0.05);且治疗组治疗后的治疗总有效率(93.88%)高于参照组(79.17%),差异有统计学意义(χ~2=4.52,P=0.03);但治疗组治疗后的不良反应发生率(6.12%)与参照组(12.50%),差异无统计学意义(χ~2=1.25,P=0.26)。结论针对小儿肺炎患儿实施布地奈德雾化吸入治疗的疗效明显,利于患儿肺功能的改善,提高患儿生活质量及预后。更多还原

【Abstract】 Objective To compare the clinical efficacy of conventional therapy and budesonide inhalation in the treatment of children with pneumonia. Methods 97 children with pediatric pneumonia admitted to our hospital were randomly divided into two groups(February to October 2018). The children in the reference group were treated with conventional therapy for 48 children with pneumonia. The treatment group was treated with 49 cases. Children with pneumonia in children underwent budesonide inhalation therapy under the premise of conventional therapy, and compared the difference in treatment effect between the two groups of children with pneumonia. Results The symptom relief time,VC level, FEV1 level and MVV level in children with pneumonia in the treatment group were better than those in the reference group(P<0.05), and the treatment group was treated. The effective rate(93.88%) was higher than that of the reference group(79.17%),the difference was statistically significant(χ~2=4.52, P=0.03); however, the incidence of adverse reactions(6.12%) after treatment in the treatment group did not differ from the reference group(12.50%),the difference was not statistical significance(χ~2=1.25,P=0.26). Conclusion The efficacy of budesonide inhalation therapy for children with pneumonia is obvious, which is beneficial to the improvement of lung function and improve the quality of life and prognosis of children.更多还原